Leerink and JPMorgan initiated coverage of Alamar Biosciences following the company’s public debut, with both banks issuing positive ratings based on NULISA assay sensitivity and automation. Alamar began trading after a $220 million initial public offering, positioning its NULISA immunoassay technology and Argo HT instrument as a differentiated proteomics platform. Analysts cited NULISA’s design to reduce background signal and the workflows that enable high sensitivity with flexible multiplexing. While Argo HT is currently for research use only, the company is developing a clinical-use version with an FDA submission planned for 2027. The initiation coverage also suggests investor focus on a credible path from research diagnostics to clinical expansion, including competitive differentiation versus other sensitivity, multiplexing, or automation offerings.